Exagen Future Growth
Future criteria checks 1/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Exagen.
Key information
11.4%
Earnings growth rate
17.5%
EPS growth rate
| Biotechs earnings growth | 48.9% |
| Revenue growth rate | 17.4% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 22 May 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 71 | -26 | -20 | -18 | 4 |
| 12/31/2024 | 56 | -29 | -26 | -25 | 6 |
| 12/31/2023 | 46 | -32 | -30 | -29 | 6 |
| 3/31/2020 | 41 | -31 | -11 | -11 | N/A |
| 12/31/2019 | 40 | -30 | -10 | -10 | N/A |
| 9/30/2019 | 40 | -31 | -8 | -8 | N/A |
| 6/30/2019 | 38 | -18 | -9 | -8 | N/A |
| 3/31/2019 | 35 | -18 | -8 | -8 | N/A |
| 12/31/2018 | 32 | -18 | -9 | -9 | N/A |
| 12/31/2017 | 27 | -33 | -12 | -11 | N/A |
| 12/31/2015 | 18 | -21 | N/A | -12 | N/A |
| 9/30/2015 | 18 | -21 | N/A | -11 | N/A |
| 6/30/2015 | 17 | -23 | N/A | -10 | N/A |
| 3/31/2015 | 15 | -17 | N/A | -10 | N/A |
| 12/31/2014 | 12 | -17 | N/A | -11 | N/A |
| 9/30/2014 | 9 | -23 | N/A | -11 | N/A |
| 6/30/2014 | 6 | -21 | N/A | -10 | N/A |
| 3/31/2014 | 4 | -19 | N/A | -8 | N/A |
| 12/31/2013 | 3 | -18 | N/A | -7 | N/A |
| 12/31/2012 | 1 | 0 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: E08A is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: E08A is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: E08A is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: E08A's revenue (17.4% per year) is forecast to grow faster than the German market (4.3% per year).
High Growth Revenue: E08A's revenue (17.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if E08A's Return on Equity is forecast to be high in 3 years time